Considering the positive prognostic value of tumor-infiltrating B cells, it might be an effective adjuvant therapy to increase intratumoral B cells via CXCL13-dependent recruitment in NPC patients with low TLS density. Here, CXCL13 is linked to nasopharyngeal carcinoma.